Accéder au contenu
MilliporeSigma

Principaux documents

Voir toute la documentation

Y0001177

Dexaméthasone

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-méthylpregna-1,4-diène-3,20-dione, 9α-Fluoro-16α-méthyl-11β,17α,21-trihydroxy-1,4-pregnadiène-3,20-dione, 9α-Fluoro-16α-méthylprednisolone, Prednisolone F

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C22H29FO5
Numéro CAS:
50-02-2
Poids moléculaire :
392.46
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329831293
MDL number:
MFCD00064136
Beilstein/REAXYS Number:
2066651
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

biological source

synthetic

grade

pharmaceutical primary standard

agency

EP

API family

dexamethasone

form

powder

packaging

pkg of 10 mg

manufacturer/tradename

EDQM

storage condition

protect from light

mp

262-264 °C

solubility

water: <0.1 g/L

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

ambient

storage temp.

2-8°C

SMILES string

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

InChI key

UREBDLICKHMUKA-CXSFZGCWSA-N

Gene Information

human ... NR3C1(2908)

General description

Dexamethasone belongs to the class of synthetic glucocorticoid steroid drugs.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dexamethasone is used as a pharmaceutical primary standard to quantify the analyte in pharmaceutical formulations using liquid chromatography (LC) technique.

Biochem/physiol Actions

Agent anti-inflammatoire du type glucocorticoïde
Agent anti-inflammatoire du type glucocorticoïde. Régule la survie, la croissance et la différenciation des lymphocytes T. Inhibe l′induction de l′oxyde nitrique synthase.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360FD

Hazard Classifications

Repr. 1B

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

S Choi et al.
British journal of anaesthesia, 112(3), 427-439 (2014-01-15)
Brachial plexus nerve blocks (BPBs) have analgesic and opioid sparing benefits for upper extremity surgery. Single-injection techniques are limited by the pharmacological duration and therapeutic index of local anaesthetics (LAs). Continuous catheter techniques, while effective can present management challenges. Off-label
Sara Bringhen et al.
Blood, 124(1), 63-69 (2014-05-24)
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who
A Keith Stewart et al.
The New England journal of medicine, 372(2), 142-152 (2014-12-09)
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. We randomly assigned 792
Afficher tous les articles scientifiques apparentés

Numéro d'article de commerce international

RéférenceGTIN
Y000117704061833806432